Skip to main content
Caplight Logo









Granata Bio

Granata Bio

Private
Duxbury, MassachusettsHealthcare & Life Scienceshttps://www.granata.bio/

Last Round

Early Funding

May 13, 2025

Total Funding Raised

$29M

Company Overview

Granata Bio is a biopharmaceutical company that develops and commercializes fertility treatments to expand therapeutic choices and enhance access for patients in North America.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

fertility therapeuticsassisted reproductive technologyARTreproductive healthfertility clinicfertility drugsspecialty pharmaceuticalbiotechnologyclinical-stage assetsreproductive endocrinologydrug developmentfertility techfemtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Granata Bio Comparables

Compare Granata Bio with similar companies based on industry and business-model similarity.

Granata Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Notify Therapeutics
79%
Igyxos Biotherapeutics
78%
Ovo Labs
77%

Granata Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingMay 13, 2025
Series A ExtensionJan 15, 2025
Series AJan 16, 2024

Key People

Founding team and executive leadership

Evan Sussman

Chief Executive Officer

Executive Team

Stephen Medeiros

Chief Operating Officer

Executive Team

Granata Bio Investors

Notable investors and investment history

Granata Bio investors
InvestorRounds
GVSeries A
Vibe BioSeries A
Amboy Street VenturesSeries A Extension, Series A
Alumni VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 13, 2026

    Open roles increased to 5, 2.5x the trailing average.

  • May 13, 2025

    Completed an early funding round.

Granata Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Granata Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Granata Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersDuxbury, Massachusetts
Employee Range18
Year Founded2018
Last FundingMay 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?